Differentiation to insulin-positive cells from human amnion epithelial cells using a pancreatic development mimicry protocol.

阅读:2
作者:Martínez-Rodríguez Daniel, Salazar-Alonso Jonathan, Castro-Abrego Axel, Ávila-González Daniela, Martínez-Alarcón Omar, Molina-Hernández Anayansi, Martínez-Juárez Alejandro, Godoy-Morales Héctor Salvador, Lara-Barragán Diana Elizabeth, Portillo Wendy, Díaz-Martínez Nestor Emmanuel, García-López Guadalupe, Díaz Nestor Fabián
Diabetes mellitus (DM) is characterized by the loss or dysfunction pancreatic β-cells. Human amniotic epithelial cells (hAEC), which retain pluripotency markers and are readily obtainable from term placentas, represent a promising alternative source of stem cells. We investigated whether hAECs can be guided through pancreatic ontogeny to generate insulin-producing β-like cells. hAEC from uncomplicated term deliveries were expanded to passage 1 and exposed to a four-stage differentiation sequence that sequentially modulated Activin/WNT, KGF/TGF-β, retinoic-acid/hedgehog, and EGF/Noggin signaling. Stage progression was monitored by end-point RT-PCR and quantitative immunofluorescence for hallmark transcription factors. After definitive endoderm induction, 64% of cells were Brachyury positive and 71% were WNT3A positive; primitive-gut specification yielded 57% HNF1B(+) cells. Posterior foregut commitment produced 75% PDX1(+) and 60% Sox9(+) nuclei and the final endocrine stage generated 74% NKX2.2(+) cells, with 71% showing cytoplasmatic insulin and 51% C-peptide staining; insulin/C-peptide co-localization was confirmed by double labelling. Thus a chemically defined, four-step protocol can convert term-derived hAEC into insulin-producing β-like cells, supporting their use as an accessible platform for diabetes modelling and future cell-replacement therapies.

特别声明

1、本文转载旨在传播信息,不代表本网站观点,亦不对其内容的真实性承担责任。

2、其他媒体、网站或个人若从本网站转载使用,必须保留本网站注明的“来源”,并自行承担包括版权在内的相关法律责任。

3、如作者不希望本文被转载,或需洽谈转载稿费等事宜,请及时与本网站联系。

4、此外,如需投稿,也可通过邮箱info@biocloudy.com与我们取得联系。